Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
4
×
boston top stories
clinical trials
4
×
deals
4
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
cancer immunotherapy
eli lilly
indiana blog main
indiana top stories
johnson & johnson
national
new york blog main
new york top stories
wisconsin blog main
wisconsin top stories
abbvie
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
cancer
car-t immunotherapy
detroit blog main
detroit top stories
fda
immunotherapy
investing
medicare
merck
nonalcoholic steatohepatitis
pembrolizumab keytruda
raleigh-durham blog main
raleigh-durham top stories
roboticsai
san diego blog main
san diego top stories
What
companies
4
×
bio
drug
nash
new
news
roundup
abandoning
ago
approval
approved
arrival
baggage
biogen’s
biopharmaceutical
biotech
convo
cuts
days
deal
development
dicerna
digital
disease
earlier
epidemic
failures
fatty
fda
free
frenzied
gets
growing
hasn’t
industry
interference
ipo
ipos
known
led
Language
unset
Current search:
biotech
×
deals
×
" clinical trials "
×
" boston blog main "
×
companies
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M